McKesson Corporation Reports Fiscal 2025 Second Quarter Results and Raises Full Year Adjusted EPS GuidanceBusiness Wire • 11/06/24
McKesson (MCK) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 10/28/24
McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent CliffSeeking Alpha • 10/09/24
InspiroGene by McKesson Unveils First-of-its-Kind Report on State of the Cell and Gene Therapy Landscape, Revealing Unparalleled Optimism Amidst Complex ChallengesBusiness Wire • 10/09/24
You Should Be Investing in Dividend Growth Stocks. These Are the 2 Best to Buy In October24/7 Wall Street • 10/02/24
McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene TherapiesBusiness Wire • 10/01/24
McKesson Corporation Announces Second Quarter Fiscal 2025 Earnings Release DateBusiness Wire • 09/23/24
Here's Why You Should Retain McKesson Stock in Your Portfolio NowZacks Investment Research • 09/19/24
McKesson (MCK) Rises Yet Lags Behind Market: Some Facts Worth KnowingZacks Investment Research • 09/12/24
McKesson Shares Fall Following Sale of Rexall, Well.ca to Birch HillZacks Investment Research • 09/06/24
S&P 500 Gains and Losses Today: McKesson Falls Amid Plans To Exit Canada BusinessesInvestopedia • 09/05/24
McKesson Corporation (MCK) Wells Fargo 2024 Healthcare Conference (Transcript)Seeking Alpha • 09/05/24
McKesson Corporation Announces Sale of Rexall and Well.ca Businesses to Birch Hill Equity PartnersBusiness Wire • 09/05/24
Wall Street Analysts See McKesson (MCK) as a Buy: Should You Invest?Zacks Investment Research • 08/28/24